Glucagon Pill

Glucagon pills refer to oral glucagon tablets, whose core physiological function is to rapidly elevate blood glucose levels. They are critical medications for hypoglycemic emergencies and indispensable life‑saving drugs in both clinical and home first aid. Hypoglycemia is defined as a blood glucose concentration below the normal range (usually fasting blood glucose < 3.9 mmol/L). If it persists for more than 6 hours, it can severely damage the central nervous system, leading to confusion, drowsiness, convulsions, coma, and even irreversible brain death, posing particularly high risks to diabetic patients, the elderly, and other vulnerable groups.

As a polypeptide hormone with effects opposite to insulin, glucagon specifically activates hepatic glycogenolytic enzymes, prompting the rapid breakdown of liver‑stored glycogen into glucose and its release into the bloodstream, thereby raising blood glucose levels quickly and restoring the patient's consciousness and basic physiological functions. The drug acts rapidly, typically producing a significant increase in blood glucose within 15–30 minutes after oral administration. It is especially suitable for the emergency treatment of sudden severe hypoglycemia in diabetic patients, buying valuable time for subsequent medical treatment.

Diabetic patients are a high‑risk group for hypoglycemia. Hypoglycemic episodes are mostly caused by excessive insulin injection, inappropriate dosage of oral hypoglycemic agents, insufficient food intake, failure to replenish energy promptly after strenuous exercise, or slowed drug metabolism due to combined hepatic or renal insufficiency.

During a severe hypoglycemic attack, patients may experience palpitations, hand tremors, sweating, and dizziness. Without timely intervention, the condition can rapidly progress to impaired consciousness, during which the patient cannot eat or consume sugary foods independently and must rely on external first aid.The greatest advantage of it lies in their non‑injectable dosage form. Compared with traditional injectable glucagon, they require no subcutaneous or intravenous injection and no professional medical personnel to administer.

Family members or the patients themselves can take the tablets orally quickly in an emergency. The convenient, non‑invasive administration enables rapid symptom relief within the golden window for hypoglycemic first aid (within 30 minutes of onset), effectively preventing dangerous outcomes such as coma, convulsions, and brain damage. This significantly improves the safety of emergency care for diabetic patients at home, outdoors, and in other settings, making it an essential emergency medication for long‑term diabetes management.

In clinical endocrine diagnosis and treatment, glucagon pills also serve as an important diagnostic agent to assist in the differential diagnosis of the causes of hypoglycemia. Some patients experience recurrent hypoglycemia of unknown origin with complex etiologies, which may include endocrine disorders such as insulinoma, hyperfunction of pancreatic islet β‑cells, hypothyroidism, or adrenocortical insufficiency, as well as external factors such as medications, diet, and exercise.

In such cases, doctors perform a glucagon stimulation test by administering a standard dose of it and collecting blood samples at various time points after administration to measure changes in the concentrations of blood glucose, insulin, C‑peptide, and related hormones, and to plot response curves. By analyzing the characteristics of these curves, the underlying cause of the patient's hypoglycemia can be determined.

For example, in patients with insulinoma, glucagon administration leads to abnormally elevated insulin secretion and slow blood glucose recovery, whereas hypoglycemia caused by external factors shows hormonal changes consistent with normal physiological patterns. This diagnostic method is accurate and safe, providing an important basis for formulating subsequent targeted treatment plans.

Beyond blood glucose‑related applications, it can also be used for adjuvant pre‑procedural preparation for gastrointestinal examinations, with their core effect being the inhibition of gastrointestinal smooth muscle peristalsis.

Excessive contraction and spasm of gastrointestinal smooth muscle accelerate peristalsis, which not only impairs the visual clarity of imaging examinations such as gastroscopy, colonoscopy, abdominal CT, and abdominal MRI but may also cause abdominal pain, bloating, nausea, and other discomforts during the procedure, even interfering with the successful completion of the examination.

By acting on specific receptors on gastrointestinal smooth muscle, glucagon inhibits smooth muscle contraction and reduces peristalsis, placing the gastrointestinal tract in a relaxed and quiescent state and stabilizing intraluminal contents.

This significantly improves the clarity of the examination field, helping physicians more accurately observe the morphology of the gastrointestinal mucosa and detect minor lesions such as polyps, ulcers, and early‑stage tumors. Meanwhile, the suppression of gastrointestinal peristalsis effectively alleviates patient discomfort during examinations, enhancing procedural comfort and compliance. Glucagon is therefore a commonly used adjuvant medication in gastrointestinal examinations.